

**Julie V. Philley, MD**  
President  
The University of Texas at Tyler | UT Tyler Health Science Center  
11937 US Highway 271 | Tyler, Texas 75708

Academic Appointments

---

<b>The University of Texas at Tyler</b> President	2024 – Present
<b>The University of Texas at Tyler</b> Vice Provost	2021 – 2024
<b>The University of Texas at Tyler Health Science Center</b> Executive Vice President for Health Affairs	2021 – 2024
Isadore Roosth Endowed Chair	2019 – 2023
Chair of Medicine	2018 – 2021
Chief of Pulmonary & Critical Care Medicine	2016 – 2020
Professor of Medicine	2020 – Present
Associate Professor of Medicine	2017 – 2020
Assistant Professor of Medicine	2012 – 2017

Education & Fellowship Training

---

<b>Lung Transplant Fellowship</b> The University of Texas Southwestern Medical Center Dallas, Texas	2011 – 2012
<b>Mycobacteria Fellowship</b> National Jewish Health Denver, Colorado	2011
<b>Pulmonary &amp; Critical Care Fellowship</b> The University of Texas Southwestern Medical Center Dallas, Texas	2009 – 2012
<b>Internal Medicine Residency</b> Johns Hopkins University / Sinai Hospital Baltimore, Maryland	2006 – 2009
<b>Doctor of Medicine</b> The University of Texas Health Science Center at Houston Houston, Texas	2006

**Bachelor of Science in Nursing** 1999  
Texas Women's University  
Denton, Texas

Tyler Junior College 1995  
Tyler, Texas

---

#### Hospital Appointments

---

The University of Texas Health Science Center at Tyler 2012 – Present  
Christus Trinity Mother Frances 2014 – 2022  
UT Health East Texas 2018 – Present  
UT Southwestern Medical Center 2009 – 2012  
Sinai Hospital (Baltimore, MD) 2006 – 2009

---

#### Licensure & Board Certifications

---

State of Texas (N3244) Active

**American Board of Internal Medicine**

Internal Medicine 2009 – Present  
Pulmonary Medicine 2011 – Present  
Critical Care Medicine 2012 – Present

---

#### Corporate & Nonprofit Board Service

---

**UT Health Tyler**

Chair, Board of Trustees 2022 – 2023  
Vice Chair, Board of Trustees 2018 – 2020

**Hospice of East Texas**

Member, Board of Directors 2023 – Present

**East Texas Crisis Center**

Member, Board of Directors 2013 – 2020  
Chair, Board of Directors 2016

**East Texas Quality Care Network**

Chair, Board of Directors 2022 – Present

**East Texas Medical Center Foundation**

Member, Board of Directors 2019 – Present

**UT Health East Texas**

Member, Board of Directors	2021 – 2024
Chair, Board of Directors	2024 – Present

<b>Teaching Hospitals of Texas</b>	2021 – Present
Member, Executive Board	

#### Academic & Community Service

---

##### **Service to the University** (*Selected*)

Chair, Faculty Senate	2016 – 2018
Member, Faculty Senate	2016 – 2018
Medical Executive Committee	2017 – Present
Academic Affiliation Committee	2018 – Present
Faculty Compensation Committee	2019 – Present
Chief of Staff	2019 – 2020
MSRDP Board of Directors & Executive Committee	2021 – 2024
Information Technology Governance Steering Committee	2023 – Present
Institutional Audit Committee	2021 – Present
Compliance Committee	2020 – Present
Handbook of Operating Procedures Committee	2021 – Present
Chair, MSRDP Board of Directors	2024 - Present

##### **Service to National Grant Review Panels, Study Sections & Committees**

Board Review:	Hospital Physician: Infectious Disease. Nontuberculous Mycobacterial Pulmonary Infection in Non-HIV Patients. Volume 15, Part 7, November 2014.
---------------	---

Peer Review:	British Medical Journal	2014 – Present
	Clinical Pulmonary Medicine	2012 – Present
	American Journal of Microbiology	2020
	Public Library of Science (PLOS)	2015
	CHEST	2012 – Present
	Bronchiectasis Registry Executive Committee	2019 – Present

Scholarship:	CHEST Foundation Bronchiectasis/NTM Review Panel	2019 – 2021
	Bronchiectasis Registry Executive Committee	2019 – 2022

##### **Service to the Community**

Women's Symphony League	2018 – Present
American Heart Circle of RED	2018 – Present
Stewardship Committee, First Presbyterian Church	2018 – 2020

#### Professional Memberships

---

Teaching Hospitals of Texas	2012 – Present
-----------------------------	----------------

Smith County Medical Society	2014 – Present
Texas Medical Association	2012 – Present
American College of Physicians	2012 – Present
American College of Chest Physicians	2012 – Present
American Thoracic Society	2012 – Present
European Respiratory Society	2014 – 2018
National Bronchiectasis Registry Committee	2019 – Present

## Honors & Awards

---

### **The University of Texas Health Science Center at Tyler**

Will Avery Faculty of the Year Award	2013
--------------------------------------	------

### **Johns Hopkins University / Sinai Hospital**

Award for Humanism and Professionalism	2009
Resident of the Year	2009
Ambulatory Care Resident Award	2009
Junior Resident of the Year	2008
Intern of the Year	2007

### **The University of Texas Health Science Center at Houston**

Hitoshi Nikaidoh Award for Humanism in Medicine	2006
---	------

## Teaching & Graduate Student Mentorship

---

### **Post-Doctoral Fellows**

Bockgie Jung, PhD	2019 – Present
-------------------	----------------

### **Teaching/Preceptorships**

Pulmonary Medicine & Critical Care, UT Health East Texas	2018 – Present
Intensive Care for Family Medicine Residents, UT Health East Texas	2012 – Present

## Speaking Engagements

---

East Texas Leadership Summit, Hispanic Business Alliance of Tyler (HPAT)	04/19/2024
Smith County Medical Society's Retired Physicians Group	04/18/2024
UT Health East Texas Q1 Leadership Conference – Keynote Speaker	03/27/2024

## Research & Extramural Support

---

### **National Institutes of Health Support (Selected)**

**Julie Philley**, MD, Investigator, Megan Devine, MD, Co-Investigator, and Carly Sigler, Coordinator. 4/10/2020. Treatment of Patients with COVID-19. CONTAIN study.

NIH-CRDF Global (INDO-US VAP phase 2). Vankayalapati, Rama (PhD) (PI) and **Philley, Julie MD** (consultant), KOI, 10/01/19-09/30/24. Identify Immunologic Markers of Persons at Highest Risk of Progression of Latent Tuberculosis Infection to Tuberculosis.

#### **Past Investigator Research Studies** *(Selected)*

Safety and Efficacy of A Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis – A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Efficacy of BMS-986020 in Subjects With Idiopathic Pulmonary Fibrosis - Clinical Protocol IM136003. Bristol-Myers Squibb Pharmaceutical Research Institute. Sub-Investigator. 2013 – 2016

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID Intermittently Administered for 28 Days on / 28 Days Off or 14 Days On / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbation in Subjects With Non-Cystic Fibrosis Bronchiectasis. Sub-Investigator. 2013 – 2016

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Subjects With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension and Pharmacokinetic Sub Study (Orbit 3). Sub-Investigator. 2014 – 2016

A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF). Principal Investigator Vertex Pharmaceuticals.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Subjects With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension (ORBIT-4). Sub-Investigator. 2014 – 2016

A Multi-Center, Randomized, Double-Blind, Crossover Study to Assess the Safety and Pharmacokinetics of Liquid Alpha1-Proteinase Inhibitor (Human) Compared to Prolastin®-C in Subjects With Alpha1-Antitrypsin Deficiency. Sub-Investigator. 2015 – 2017

A Randomized, Double-Blind, Chronic Dosing (56 week) Placebo-Controlled, Parallel Group, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab (MEDI-563) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (GALATHEA). Sub-Investigator. 2014 – 2017

A 26 Week, Randomized, Active-Controlled Safety Study of Double-Blind Formoterol Fumarate in Free Combination With an Inhaled Corticosteroid Versus an Inhaled Corticosteroid in Adolescent and Adult Patients With Persistent Asthma. Sub-Investigator. 2014 – 2016

A Randomized, Open-Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium avium Complex (MAC) that are Refractory to Treatment – INS-212. Sub-Investigator. 2015 – 2019

A Multicenter, Randomized, Double-Blind, Parallel group, Placebo Controlled, Phase 3 study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid Use in Adults and Adolescents with Oral Corticosteroid Dependent Asthma (TROPOS). Sub-Investigator. 2013 – 2014

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to have Residual Function – Protocol VX14-661-108. Principal Investigator. 2015 – 2017

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-3 (Glycopyrrolate For Obstructive Lung Disease Via Electronic Nebulizer) SUN101-301. Sub-Investigator. 2015

A Phase IIa, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066 as Add-On Therapy Over 24 Weeks in Patients With Severe Persistent Asthma. Sub-Investigator. 2015 – 2017

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID Intermittently Administered for 28 Days On / 28 Days Off or 14 Days On / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis. Sub-Investigator. 2015

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis – A Safety and Efficacy Trial in Adult Cystic Fibrosis Subjects – DPM-CF-303. Principal Investigator. 2015 – 2017

An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium avium Complex (MAC) That are Refractory to Treatment – INS-312. Sub-Investigator. 2015 – 2019

A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F) - Protocol VX17-445-103. Principal Investigator. 2018

A Phase 3, Open-Label Study Evaluating the Long-Term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation - Protocol VX17-445-105. Principal Investigator. Vertex Pharmaceuticals. 2018

### **Principal Investigator Studies**

Circulating Inflammatory Biomarkers in Chronic Lung Disease Patients With or Without Nontuberculous Mycobacterial Disease. Sponsor: PI Initiated. 2017 – 2022

Breast Cancer Gene Analysis in Patients With Non CF Bronchiectasis. Sponsor: PI initiated. 2017 – 2022

Clinical Data Related to Estrogen in Women With Bronchiectasis With or Without Nontuberculous Mycobacterial Disease (NTM). Sponsor: PI Initiated. – 2022

Multi-National Comparison Analysis Using Quantitative Radiological Evaluation in MAC Pulmonary Disease (MACPD). Sponsor: PI Initiated. 2017 – Current

Determining the Effectiveness of Airway Clearance on Subjects With Bronchiectasis. Sponsor: PI Initiated. 2017 – Current

Assessment of Anxiety and Depression in Non-CF Bronchiectasis Patients. Sponsor: PI Initiated. 2018– 2021

Bronchiectasis Research Registry: A Consolidated Database of Non-Cystic Fibrosis Bronchiectasis Patients from Major Clinical and Research Institutions (Registry). Principal Investigator Sponsor: COPD Foundation. 2010 – Current

Circulating Inflammatory Biomarkers in Patients With Chronic Lung Disease With and Without Nontuberculous Mycobacterial Lung Infection (Blood Draw). Sponsor: PI Initiated. 2013 – 2018

Clinical Disease, Treatment, and Outcomes for Patients Infected With *Mycobacterium abscessus* (Chart Review). Sponsor: PI Initiated 2013 – 2023

Bedaquiline in Refractory *Mycobacterium Avium* Complex and *Mycobacterium abscessus* Patients (Blood Draw). Sponsor: PI Initiated. 2013 - 2020

Breast Cancer Gene Analysis in Patients With Non-CF Bronchiectasis (Blood Draw). Sponsor: PI Initiated. 2014 – 2022

Biospecimen Banking and Biomarker Validation for Lung Cancer Early Detection in Cohort Receiving Low Dose Helical Computed Tomography Screening (Registry). Principal Investigator. MD Anderson Center. 2015 – Current

Use of Clofazimine for the Treatment of Nontuberculous Mycobacterial (NTM) Infections in Patients With Limited Therapeutic Options (Compassionate Use). Principal Investigator. Novartis. 2015 – 2023

A Phase IIA, Two-Part, Randomized, Multi-Center, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study To Compare the Efficacy and Safety of BCT197 When Added On To Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) Requiring Hospitalization in Adults – Protocol MBCT206. Sub-Investigator. 2018

An Exploratory, Prospective, Open-Label Study of Efficacy, Safety and Tolerability of Liposomal Amikacin for Inhalation (LAI) Once Daily Multidrug Treatment of *Mycobacterium abscessus* Lung Disease. Principal Investigator. Insmid Incorporate. 2016 – 2023

Clofazimine in the Treatment of Pulmonary *Mycobacterium avium* Complex (MAC) Disease – (MAC-CLOFAZ-001). Principal Investigator. Novartis. 2016 – 2022

Liposomal Amikacin for Inhalation for the Treatment of Nontuberculous Mycobacterium (Compassionate Use Study) Principal Investigator. Insmed Corporation. 2017

Multiple Patient Program for Lamprene (Clofazimine) for the Treatment of Non-Tuberculous Mycobacterial (NTM) Infections (Compassionate Use). Principal Investigator. Novartis. 2017 – 2023

A Phase 4, Multicenter, Randomized, Double-Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Pulmonary Sarcoidosis. Principal Investigator. Mallinckrodt. 2018

A Double-Blind, Placebo-Controlled, Multicenter, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-Cystic Fibrosis Bronchiectasis Chronically Infected With *Pseudomonas Aeruginosa* (*P. Aeruginosa*). Principal Investigator. Zambon SpA. 2017

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety and Tolerability, and Pharmacokinetics of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis – The Willow Study. Principal Investigator. Insmed Corporation. 2018 – 2023

An Open-Label, Multicenter Study to Evaluate the Long-Term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human), Modified Process 60 mg/kg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin Deficiency. Sub-Investigator. Grifols Therapeutics Inc. 2019 – 2021

Multicenter Randomized Pragmatic Clinical Trial Comparing Two-Versus Three-Antibiotic Therapy for Pulmonary *Mycobacterium avium* Complex Disease. Principal Investigator. Oregon Health & Science Univ / Patient Centered Outcomes Research Institute. 2019 – 2023

Clinical Effectiveness of High Frequency Chest Wall Oscillation (HFCWO) In A Bronchiectasis Population. Principal Investigator. Electromed Incorporated. 2019 – 2023

A Phase 1 Multi-Center Study to Measure the Pharmacokinetics of Oral Omadacycline in Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP). Principal Investigator. Paratek Pharmaceuticals, Inc. 2019 – 2023

Evaluation of HFCWO Using the Vest® System for Treatment of Non-Cystic Fibrosis Bronchiectasis in the Home Setting. Principal Investigator. Hill-Rom Company, Inc. 2019 –2023

Qualitative Interviews to Support PRO Measurement Development in Patients With *Mycobacterium avium* Complex (MAC) or *Mycobacterium abscessus* (MAbs) Lung Infection. Principal Investigator. Insmed Inc. 2019 – 2023

### **Selected Abstracts**

Boorgula GD, Gumbo T, Singh S, McShane PJ, **Phillely JV**, Srivastava S, Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation., *Tuberculosis*, 2024.

Singh S, Gumbo T, Boorgula GD, Thomas TA, **Phillely JV**, Srivastava S. Omadacycline



pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant *Mycobacterium tuberculosis* in the hollow fiber system model. Antimicrob Agents Chemother. 2024 Feb 7

Singh S, Boorgula GD, Aryal S, **Philley JV**, Gumbo T, Srivastava S. Sarecycline pharmacokinetics/pharmacodynamics in the hollow-fibre model of *Mycobacterium avium* complex: so near and yet so far. J Antimicrob Chemother. 2024 Jan 3

J.A. Hawkins, S.A.R. Siegel, E. Henkle, J. Ali, W. Miller, P.J. McShane, **J.V. Philley**, C.L. Daley, D.E. Griffith, K.L. Winthrop. Clofazimine in the Treatment of Pulmonary *Mycobacterium Avium* Complex (MAC) Disease. ATS, 2024.

P.J. McShane, R.N. Wilsey, T.N. Koch, K.T. Dean, M.M. Terrell, E.R. Dohanich, T. Drake, **J.V. Philley**, J.R. Honda. Recovery and identification of *Mycobacterium abscessus* and *Mycobacterium avium* complex from home environmental samples of patients with nontuberculous mycobacterial lung disease. WBC, 2024.

Yoon H, Li Y, Goldfeld KS, Cobb GF, Sturm-Reganato CL, Ostrosky-Zeichner L, Jayaweera DT, **Philley JV**, Desruisseaux MS, Keller MJ, Hochman JS, Pirofski LA, Ortigoza MB; CONTAIN-Extend Study Group. COVID-19 Convalescent Plasma Therapy: Long-term Implications. Open Forum Infect Dis. 2023 Dec 29

El Ghali A, Morrisette T, Alosaimy S, Lucas K, Tupayachi-Ortiz MG, Vemula R, Wadle C, **Philley JV**, Mejia-Chew C, Hamad Y, Stevens RW, Zeuli JD, Webb AJ, Fiske CT, Simonyan A, Cimino CL, Mammadova M, Umana VE, Hasbun R, Butt S, Molina KC, Thomas M, Kaip EA, Bouchard J, Gore TW, Howard C, Cabanilla MG, Holger DJ, Frens JJ, Barger M, Ong A, Cohen KA, Rybak MJ. Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes. Antimicrob Agents Chemother. 2023 Oct 18.

Siegel SAR, Griffith DE, **Philley JV**, Brown-Elliott BA, Brunton AE, Sullivan PE, Fuss C, Strnad L, Wallace RJ Jr, Winthrop KL. Open-Label Trial of Amikacin Liposome Inhalation Suspension in *Mycobacterium abscessus* Lung Disease. Chest. 2023 Oct.

Singh S, Wang JY, Heysell SK, McShane PJ, Wadle C, Shankar P, Huang HL, Pasipanodya J, Boorgula GD, **Philley JV**, Gumbo T, Srivastava S. Omadacycline pharmacokinetics/ pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary *Mycobacterium abscessus* disease. Int J Antimicrob Agents. 2023 Jul.

Flume PA, Basavaraj A, Garcia B, Winthrop K, Di Mango E, Daley CL, **Philley JV**, Henkle E, O'Donnell AE, Metersky M. Towards development of evidence to inform recommendations for the evaluation and management of bronchiectasis. Respir Med. 2023 May.

Asif H, Rahaghi FF, Ohsumi A, **Philley J**, Emtiazjoo A, Hiram T, Baker AW, Shu CC, Silveira F, Poulin V, Rizzuto P, Nagao M, Burgel PR, Hays S, Aksamit T, Kawasaki T, Dela Cruz C, Aliberti S, Nakajima T, Ruoss S, Marras TK, Snell GI, Winthrop K, Mirsaeidi M. Management of

nontuberculous mycobacteria in lung transplant cases: an international Delphi study. ERJ Open Res. 2023 Mar 27.

L. Farahani, P. J. McShane, T. Drake<sup>2</sup>, B. A. Brown-Elliott, **J. Philley**, R. J. Wallace, D. Griffith, S. H. Kasperbauer, Bedaquiline Treatment as Salvage Therapy for Nontuberculous Mycobacterial Pulmonary Disease. ATS, 2023

B. Yao, K. Sarva, G. Florova, R. Hibbard, M. Devine, **J. Philley**, S. Idell, D. D. McPherson, A. Komissarov Fibrinolysis and Inflammation in Convalescent Plasma Treated COVID-19 Patients. ATS, 2023.

Jung BG, Dean K, Wadle C, Samten B, Tripathi D, Wallace RJ Jr, Brown-Elliott BA, Tucker T, Idell S, **Philley JV**, Vankayalapati R. Decreased Interleukin-1 Family Cytokine Production in Patients with Nontuberculous Mycobacterial Lung Disease. Microbiol Spectr. 2022 Dec 21.

Jung BG, Samten B, Dean K, Wallace RJ Jr, Brown-Elliott BA, Tucker T, Idell S, **Philley JV**, Vankayalapati R. Early IL-17A production helps establish Mycobacterium intracellulare infection in mice. PLoS Pathog. 2022 Apr 1.

Srivastava S, Pasipanodya JG, Heysell SK, Boorgula GD, Gumbo T, McShane PJ, **Philley JV**. An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease. J Glob Antimicrob Resist. 2022 Mar.

Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O'Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, **Philley JV**, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA; CONTAIN COVID-19 Consortium for the CONTAIN COVID-19 Study Group; Parameswaran L, Corcoran AT, Rohatgi A, Wronska MW, Wu X, Srinivasan R, Deng FM, Filardo TD, Pendse J, Blaser SB, Whyte O, Gallagher JM, Thomas OE, Ramos D, Sturm-Reganato CL, Fong CC, Daus IM, Payoen AG, Chiofolo JT, Friedman MT, Wu DW, Jacobson JL, Schneider JG, Sarwar UN, Wang HE, Huebinger RM, Dronavalli G, Bai Y, Grimes CZ, Eldin KW, Umana VE, Martin JG, Heath TR, Bello FO, Ransford DL, Laurent-Rolle M, Shenoi SV, Akide-Ndunge OB, Thapa B, Peterson JL, Knauf K, Patel SU, Cheney LL, Tormey CA, Hendrickson JE. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 Feb 1.

Ku JH, Siegel SAR, **Philley J**, Schipper P, Thanawala R, Hendrick MA, Sigler C, Strnad L, McShane P, Griffith D, Tieu B, Caccitolo J, Fuss C, Le A, Winthrop K. Outcomes of Resectional Thoracic Surgery for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease in 105 Patients in the United States. Chest. 2022 Feb.

Jung BG, Dean K, Samten B, Wallace RJ Jr., Brown-Elliott BA, Tucker TA, Idell S, **Philley JV**, Vankayalapati R. Early IL-17A production helps establish Mycobacterium *intracellulare* infection in mice. Keystone Symposia Conference, 2022.

Terada, Ross S.; Dean, Kristin; Greenlee, Kimberly L.; Drake, Tracy J.; **Philley, Julie V.**; Jung, Bock-Gie; McShane,

- Pamela J. Immune Profiles in Bronchiectasis Patients With and without MAC Lung Disease. ATS. 2022.
- Henkle, E.; **Philley, J.**; Addrizzo-Harris, DJ; Daley, CL; Griffith, DE; Aksamit, TR; Swenson, C.; Ruoss, SJ; Marras, TK; Brunton, AE; Winthrop, KL. Self-reported symptom and adverse event profiles in macrolide-based oral treatment of *Mycobacterium avium* complex pulmonary disease. ATS, 2022.
- Philley, Julie V.**; Deck, Daniel H.; Sirbu, Alissa; Das, Anita F.; Serio, Alisa W.; Brenner, Randy; Berman, Gail; Winthrop, Kevin. Omadacycline in *M. abscessus* Pulmonary Disease. Colorado Mycobacteria Conference, 2022.
- Metersky ML, Choate R; Bronchiectasis and NTM Research Registry Investigators. The Association of Long-term Macrolide Therapy and Nontuberculous Mycobacterial Culture Positivity in Patients With Bronchiectasis. Chest. 2021 Aug.
- McShane PJ, **Philley JV**, Prieto DA, Aksamit TR. Global Attitudes of Health Care Providers About Aerosolized Airway Clearance Therapy in Bronchiectasis Patients During the Coronavirus Disease 2019 Pandemic. Chronic Obstr Pulm Dis. 2021 Jul 28.
- Henkle, E.; Quittner, A.L.; Brunton, Al.; Marras, T.K.; Flume, P.; Addrizzo-Harris, D.; Ali, J.; **Philley, J.**; Whinthrop, K.L.. Respiratory Symptoms and Health Perception Improve Rapidly in Patients Treated for Pulmonary *Mycobacterium Avium* Complex Disease. ATS, 2021.
- Ku, Jennifer MPH; Siegel, Sarah MPH; Schipper, Paul MD; Tieu, Brandon MD; Hendrick, Andie MPH; Sigler, Carly BS; Strnad, Luke MD; Fuss, Cristina MD; Caccitolo, James MD; **Philley, Julie MD**. ATS, 2020. Surgical Outcome of Resectional Thoracic Surgery for The Treatment of Nontuberculous Mycobacterial Pulmonary Disease in 98 U.S. Patients. ATS, 2020
- Philley, Julie V. MD**; Guthrie, Christiana MPA, RRT; Sigler, Carly BS; Solomon, George M. MD; Kirkpatrick, DeNay CRNP. CHEST, 2019. Correlation of Anxiety in Patients With Non-Cystic Fibrosis Bronchiectasis Patients. CHEST, 2019.
- Sigler, Carly BS; Guthrie, Christiana MPA, RRT; Griffith, David E., MD; Singh, Karan PhD; Ndetan, Harrison MPH, MD, PhD; **Philley, Julie V. MD**. NYU, 2018. Determining the Effectiveness of Airway Clearance in Subjects With Non- Cystic Fibrosis Bronchiectasis. NYU, 2018.
- Philley, JV**; Devine, SD; Calhoun, KM; Thakkar, FM; Brown-Elliott, B.; Wallace, Jr. RJ; Griffith, DE. Macrolide Resistant *Mycobacterium Avium* Complex Pulmonary Disease Treated With Bedaquiline. ATS 2018. P>A5917.
- Watston, Seigal S.; **Philley, J.**; Thakakar, F.; Devine, M.S.; Ku, Caccitolo J.; Winthrop, J.H. K.E. Video-Assisted Thoracoscopic Surgery (VATS) for Nontuberculous Mycobacterial Lung Disease in the Setting of Structural Lung Disease. ATS, 2018. pA2612.
- Philley, Julie**, Guthrie, Christiana, Whitehead, Starla, Cook, Amber, Benwill, Jeana, Brown-Elliott, Barbara, Wallace, Richard, Griffith, David. A Possible Association Between Breast Cancer, Bronchiectasis and Nontuberculous Mycobacterial (NTM) Lung Disease. ERS: 2014.

**Philley, Julie;** Iakhiaeva, Elena; McNulty, Steven; Brown-Elliott, Barbara A.; Falkinham, III Joseph O.; Williams, Myra D.; Vasireddy, Ravikiran; Vasireddy, Sruthi; Wilson, Rebecca W.; Griffith, David E.; Turenne, Christine; Benwill, Jeana; Stout, Jason E.; Wallace Jr., Richard J. Clinical and Laboratory Features of Respiratory Isolates of Mycobacterium *Chimaera*. ATS, 2014.

Griffith, David; **Philley, Julie;** Brown-Elliott, Barbara; Wallace, Richard. Isolation of *M. abscessus* From Patients With *M. avium* Complex (MAC) Lung Disease. ERS, 2013.

Arauco-Brown, Alfredo MD; **Philley, Julie MD;** Battaile, John MD. Inhaled Corticosteroid Use in COPD is Not Associated With an Increased Likelihood of Airway Colonization With NTM. ATS, 2013.

Weldon, Chad DO; **Philley, Julie MD;** Hlavarty, Amy MD; Menard, Ryan MD. What's in Your Supplement? Sarcoidosis Precipitated by Over-the-Counter. Hormone Supplementation. ATS, 2103.

**Philley, Julie MD;** Newton, Chad M.D.; Battaile, John M.D. Gastric Acid Suppression May Influence the Likelihood of Isolating Nontuberculous Mycobacteria from the Airways of Individuals With COPD. ACCP, 2011.

**Philley, Julie MD;** Battaile, John M.D. Isolation of Nontuberculous Mycobacteria from Airway Culture is Associated With an Increased Likelihood of COPD Exacerbation Within One Year. ATS, 2011.

**Philley, Julie MD;** Battaile, John M.D. Airway Colonization With Multiple Strains of Nontuberculous Mycobacteria is More Likely in Patients With Severe COPD. ACCP, 2010.

## Publications

---

### Books/Chapters

Jung BG, Dean K, Wadle C, Samten B, Tripathi D, Wallace RJ Jr., Brown-Elliott BA, Tucker TA, Idell S, **Philley JV,** Vankayalapati R. Decreased IL-1 family cytokine production in patients with nontuberculous mycobacterial lung disease. *Microbacterial Spectrum*.

**Philley, Julie V.** "Medical Management of Pulmonary Nontuberculous Mycobacterial Disease." *Surgery for Pulmonary Mycobacterial Disease*, by John D. Mitchell, 1st ed., vol. 29, Elsevier, 2019, pp. 65–76.

**Philley, Julie V.** "Nontuberculous Mycobacterial Disease in Transplant Recipients." *Principles and Practice of Transplant Infectious Diseases*, by Amar Safdar, Springer, 2019, pp. 503–517.

**Philley, Julie V.** "Antimycobacterial Consideration in Transplantation Including Drug Non-Susceptibility and Resistance: Tuberculosis and Nontuberculous Mycobacterial Disease." *Principles and Practice of Transplant Infectious Diseases*, by Amar Safdar, Springer, 2019, pp. 1003-1017.

**Philley, Julie V.** "Diseases Due to Nontuberculous Mycobacteria." *Fishman's: Pulmonary Diseases and Disorders* by Michael A. Grippi, MD, 5th ed., vol. 2, McGraw Hill Education, 2015, pp. 2032-2038.

### Journal Articles

**Philley JV**, Griffith DE. Management of Nontuberculous Mycobacterial (NTM) Lung Disease. *Semin Respir Crit Care Med*. 2013, Feb;34(1):135-42.

Wallace RJ Jr, Brown-Elliott BA, McNulty S, **Philley JV**, Killingley J, Wilson RW, York DS, Shepherd S, Griffith DE. Macrolide/Azalide Therapy for Nodular/Bronchiectatic: *Mycobacterium avium* Complex Lung Disease. *Chest*. 2014 Aug;146(2):276-282.

Canadian Association of Pathologists Telepathology Guidelines Committee, Bernard C, Chandrakanth SA, Cornell IS, Dalton J, Evans A, Garcia BM, Godin C, Godlewski M, Jansen GH, Kabani A, Louahlia S, Manning L, Maung R, Moore L, **Philley J**, Slatnik J, Srigley J, Thibault A, Picard DD, Cracower H, Tetu B. Guidelines from the Canadian Association of Pathologists for Establishing a Telepathology Service for Anatomic Pathology Using Whole-Slide Imaging. *J Pathol Inform*. 2014 Mar 28;5(1):15.

Griffith, DE, **Philley, J.**, Aksamit, T. Nontuberculous Mycobacterial (NTM) Lung Disease: The Top Ten Essentials. *Respir Med*. 2014 Mar;108(3):417-25.

Griffith DE, **Philley JV**, Brown-Elliott BA, Benwill J, Shepherd S, York D, Wallace RJ Jr. The Significance of *M. abscessus ssp abscessus* Isolation During *Mycobacterium avium* Complex (MAC) Lung Disease Therapy. *Chest*. 2014 Oct 30.

**Philley, Julie V.**; Wallace, Richard J.; Benwill, Jeana L.; Taskar, Varsha; Brown-Elliott, Barbara A.; Thakkar, Foram; Aksamit, Timothy R.; Griffith, David E.; Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease, *Chest*. 2015 Aug; 148(2): 499–506. Published online 2015 Feb 12.

**Philley JV**, Griffith DE. Treatment of Slowly Growing Mycobacteria. *Clin Chest Med*. 2015 Mar;36(1):79-90.

**Philley JV**, Griffith DE. Impulse Oscillometry and Bronchiectasis. We Still Haven't Found What We're Looking For? *An Am Thorac Soc*. 2015 May;12(5):621-2.

Griffith, David E.; Adjemian, Jennifer; Brown-Elliott, Barbara A.; **Philley, Julie V.**; Prevots, D. Rebecca; Gaston, Christopher; Olivier, Kenneth N.; Wallace, Jr. Richard J. Semiquantitative Culture Analysis during Therapy for *Mycobacterium avium* Complex Lung Disease. *Am J Respir Crit Care Med*. 2015 Sep 15; 192(6): 754–760.

Griffith DE, Adjemian J, Brown-Elliott BA, Prevots DR, **Philley JV**, Olivier KN, Wallace RJ Jr. Reply: Cure Not Possible, by Definition. *Am J Respir Crit Care Med*. 2015 Nov 15;192(10):1256-7.

Kannan A, Wells RB, Sivakumar S, Komatsu S, Singh KP, Samten B, **Philley JV**, Sauter ER, Ikebe M, Idell S, Gupta S, Dasgupta S. Mitochondrial Reprogramming Regulates Breast Cancer Progression. *Clin Cancer Res*. 2016 Jul 1;22(13):3348-60.

**Philley JV**, Kannan A, Dasgupta S. MDA-9/Syntenin Control. *J Cell Physiol*. 2016 Mar;231(3):545-50.

**Philley JV**, Kannan A, Qin W, Sauter ER, Ikebe M, Hertweck KL, Troyer DA, Semmes OJ, Dasgupta S. Complex-I Alteration and Enhanced Mitochondrial Fusion Are Associated With Prostate Cancer Progression. *J Cell Physiol*. 2016 Jun;231(6):1364-74.

- Tortoli E, Kohl TA, Brown-Elliott BA, Trovato A, Leão SC, Garcia MJ, Vasireddy S, Turenne CY, Griffith DE, **Phillely JV**, Baldan R, Campana S, Cariani L, Colombo C, Taccetti G, Teri A, Niemann S, Wallace RJ Jr, Cirillo DM. Emended Description of *Mycobacterium abscessus*, *Mycobacterium abscessus* subsp. *abscessus* and *Mycobacterium abscessus* subsp. *Bolletii* and Designation of *Mycobacterium abscessus* subsp. *Massiliense* Comb. Nov. Int J Syst Evol Microbiol. 2016 Nov;66(11):4471-4479.
- Phillely JV**, DeGroot MA, Honda JR, Chan MM, Kasperbauer S, Walter ND, Chan ED. Treatment of Non-Tuberculous Mycobacterial Lung Disease. Curr Treat Options Infect Dis. 2016 Dec;8(4):275-296.
- Brown-Elliott BA, **Phillely JV**. Rapidly Growing Mycobacteria. Microbiol Spectr. 2017 Jan;5(1). Jan;5(1). doi: 10.1128/microbiolspec.TNMI7-0027-2016.
- Brown-Elliott BA, **Phillely JV**, Griffith DE, Thakkar F, Wallace RJ Jr. In Vitro Susceptibility Testing of Bedaquiline against *Mycobacterium avium* Complex. Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01798-16.
- Alexander DC, Vasireddy R, Vasireddy S, **Phillely JV**, Brown-Elliott BA, Perry BJ, Griffith DE, Benwill JL, Cameron AD, Wallace RJ Jr. Emergence of mmpT5 Variants during Bedaquiline Treatment of *Mycobacterium Intracellulare* Lung Disease. J Clin Microbiol. 2017 Feb;55(2):574-584.
- Brown-Elliott BA, **Phillely JV**, Griffith DE, Thakkar F, Wallace RJ Jr. In Vitro Susceptibility Testing of Bedaquiline against *Mycobacterium avium* Complex. Antimicrob Agents Chemother. 2017 Jan 24;61(2) pii: e01798-16.
- Phillely JV**, Kannan A, Griffith DE, Devine MS, Benwill JL, Wallace RJ Jr, Brown-Elliott BA, Thakkar F, Taskar V, Fox JG, Alqaid A, Bains H, Gupta S, Dasgupta S. Exosome Secretome and Mediated Signaling in Breast Cancer Patients With Nontuberculous Mycobacterial Disease. Oncotarget. 2017 Mar 14;8(11):18070-18081.
- Griffith DE, **Phillely JV**. The new "Hesitation Blues": Initiating *Mycobacterium Avium* Complex Lung Disease Therapy. Eur Respir J. 2017 Mar 8;49(3).
- Kannan A, Hertweck KL, **Phillely JV**, Wells RB, Dasgupta S. Genetic Mutation and Exosome Signature of Human Papilloma Virus Associated Oropharyngeal Cancer. Sci Rep. 2017 Apr 6;7:46102.
- Tortoli E, Kohl TA, Brown-Elliott BA, Trovato A, Cardoso-Leão S, Garcia MJ, Vasireddy S, Turenne CY, Griffith DE, **Phillely JV**, Niemann S, Wallace RJ, Cirillo DM. *Mycobacterium abscessus*, a Taxonomic Puzzle. Int J Syst Evol Microbiol. 2018 Jan;68(1):467-469. doi: 10.1099/ijsem.0.002457. Epub 2017 Nov 15.
- Phillely JV**, Hertweck KL, Kannan A, Brown-Elliott BA, Wallace RJ Jr, Kurdowska A, Ndetan H, Singh KP, Miller EJ, Griffith DE, Dasgupta S. Sputum Detection of Predisposing Genetic Mutations in Women With Pulmonary Nontuberculous Mycobacterial Disease. Sci Rep. 2018 Jul 27;8(1):11336.
- Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, **Phillely JV**, Wallace RJ Jr, van Ingen J, Coulter C, Nezamis J, Winthrop KL; CONVERT Study Group. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by *Mycobacterium avium* Complex (CONVERT): A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569.

- Philley JV**, Kannan A, Olusola P, McGaha P, Singh KP, Samten B, Griffith DE, Dasgupta S. Microbiome Diversity in Sputum of Nontuberculous Mycobacteria Infected Women With a History of Breast Cancer. *Cell Physiol Biochem*. 2019;52(2):263-279.
- Philley JV**, Griffith DE. Medical Management of Pulmonary Nontuberculous Mycobacterial Disease. *Thorac Surg Clin*. 2019 Feb;29(1):65-76.
- Olusola P, Banerjee HN, **Philley JV**, Dasgupta S. Human Papilloma Virus-Associated Cervical Cancer and Health Disparities. *Cells*. 2019 Jun 21;8(6). pii: E622.
- Kannan A.; **Philley JV**.; Hertweck KL.; Ndetan H.; Singh KP.; Sivakumar S.; Wells RB.; Vadlamudi RK.; Dasgupta S. Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles. *Sci Rep*. 2019 Aug 12;9(1):11632.
- Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibila O, O'Donnell AE, Sullivan EJ, Mange KC, Fernandez C, Zou J, Daley CL; WILLOW Investigators. Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. *N Engl J Med*. 2020 Nov 26;383(22):2127-2137.
- Despotes KA, Choate R, Addrizzo-Harris D, Aksamit TR, Barker A, Basavaraj A, Daley CL, Eden E, DiMango A, Fennelly K, **Philley J**, Johnson MM, McShane PJ, Metersky ML, O'Donnell AE, Olivier KN, Salathe MA, Schmid A, Thomashow B, Tino G, Winthrop KL, Knowles MR, Daniels MLA, Noone PG. Nutrition and Markers of Disease Severity in Patients With Bronchiectasis. *Chronic Obstr Pulm Dis*. 2020 Oct;7(4):390-403.
- Morrisette T, Alosaimy S, **Philley JV**, Wadle C, Howard C, Webb AJ, Veve MP, Barger ML, Bouchard J, Gore TW, Lagnf AM, Ansari I, Mejia-Chew C, Cohen KA, Rybak MJ. Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium *abscessus* Infections. *Open Forum Infect Dis*. 2021 Jan 7;8(2).
- Cook A, Sigler C, Allen L, Peters JA, Guthrie C, Marroquin M, Ndetan H, Singh KP, Murry J, Norwood S, **Philley JV**. Burnout and Anxiety Among Trauma Nursing Specialties in a Rural Level I Trauma Center. *J Trauma Nurs*. 2021 Jan-Mar 01;28(1):26-36.
- McShane PJ, **Philley JV**, Prieto DA, Aksamit TR. Global Attitudes of Health Care Providers About Aerosolized Airway Clearance Therapy in Bronchiectasis Patients During the Coronavirus Disease 2019 Pandemic. *Chronic Obstr Pulm Dis*. 2021 Jul 28;8(3):319-325.
- Metersky ML, Choate R; Bronchiectasis and NTM Research Registry Investigators. The Association of Long-term Macrolide Therapy and Nontuberculous Mycobacterial Culture Positivity in Patients With Bronchiectasis. *Chest*. 2021 Aug;160(2):466-469.
- Idell S, McPherson DD, Martin J, Dentino A, Ostrosky-Zeichner L, **Philley JV**, McGaha P, Devine M, Bronicki J, Karp DD. J Health Care Poor Underserved. 2022;33(1):517-527.
- Jung BG, Dean K, Samten B, Wallace RJ Jr., Brown-Elliott BA, Tucker TA, Idell S, **Philley JV**, Vankayalapati R. Early IL-17A production helps establish Mycobacterium *intracellulare* infection in mice. *PLoS Pathog*. 2022 Apr;18(4):e1010454.
- Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O'Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, **Philley JV**, Pirofski LA; et al.

CONTAIN. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial. *JAMA Intern Med.* 2022 Feb 1;182(2):115-126.

Jung BG, Dean K, Wadle C, Samten B, Tripathi D, Wallace RJ Jr, Brown-Elliott BA, Tucker T, Idell S, **Phillely JV**, Vankayalapati R. Decreased Interleukin-1 Family Cytokine Production in Patients with Nontuberculous Mycobacterial Lung Disease. *Microbiol Spectr.* 2022 Dec 21;10(6).

Srivastava S, Pasipanodya JG, Heysell SK, Boorgula GD, Gumbo T, McShane PJ, **Phillely JV**. An overview of drugs for the treatment of Mycobacterium *kansasii* pulmonary disease. *J Glob Antimicrob Resist.* 2022 Mar;28:71-77.

Ku JH, Siegel SAR, **Phillely J**, Schipper P, Thanawala R, Hendrick MA, Sigler C, Strnad L, McShane P, Griffith D, Tieu B, Caccitolo J, Fuss C, Le A, Winthrop K. Outcomes of Resectional Thoracic Surgery for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease in 105 Patients in the United States. *Chest.* 2022 Feb;161(2):365-369.

Asif H, Rahaghi FF, Ohsumi A, **Phillely J**, Emtiazjoo A, Hiramata T, Baker AW, Shu CC, Silveira F, Poulin V, Rizzuto P, Nagao M, Burgel PR, Hays S, Aksamit T, Kawasaki T, Dela Cruz C, Aliberti S, Nakajima T, Ruoss S, Marras TK, Snell GI, Winthrop K, Mirsaiedi M. Management of nontuberculous mycobacteria in lung transplant cases: an international Delphi study. *ERJ Open Res.* 2023 Mar 27;9(2):00377-2022.

Flume PA, Basavaraj A, Garcia B, Winthrop K, Di Mango E, Daley CL, **Phillely JV**, Henkle E, O'Donnell AE, Metersky M. Towards development of evidence to inform recommendations for the evaluation and management of bronchiectasis. *Respir Med.* 2023 May;211:107217.

Singh S, Wang JY, Heysell SK, McShane PJ, Wadle C, Shankar P, Huang HL, Pasipanodya J, Boorgula GD, **Phillely JV**, Gumbo T, Srivastava S. Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium *abscessus* Disease. *Int J Antimicrob Agents.* 2023 May 13:106847.

Seigel, SR, Griffith, DE, **Phillely, JV**, Brown-Elliott, B, Brunton, A, Sullivan, P, Fuss, C, Strnad, L, Wallace, RJ, Winthrop KL. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium *abscessus* Lung Disease. *Chest.* 2023 Jun 17:S0012-3692(23).

Henkle E, Quittner AL, Dieckmann NF, Franklin H, Brunton AE, Daley CL, Winthrop KL; **MAC2v3 Investigators**. Patient-Reported Symptom and Health-Related Quality-of-Life Validation and Responsiveness During the First 6 Months of Treatment for Mycobacterium *avium* Complex Pulmonary Disease. *Chest.* 2023 Jul;164(1):53-64.

Yoon H, Li Y, Goldfeld KS, Cobb GF, Sturm-Reganato CL, Ostrosky-Zeichner L, Jayaweera DT, **Phillely JV**, Desruisseaux MS, Keller MJ, Hochman JS, Pirofski LA, Ortigoza MB; CONTAIN-Extend Study Group. COVID-19 Convalescent Plasma Therapy: Long-term Implications. *Open Forum Infect Dis.* 2023 Dec 29;11(1).

Singh S, Boorgula GD, Aryal S, **Phillely JV**, Gumbo T, Srivastava S. Sarecycline pharmacokinetics/pharmacodynamics in the hollow-fibre model of Mycobacterium *avium* complex: so near and yet so far. *J Antimicrob Chemother.* 2024 Jan 3;79(1):96-99.

Singh S, Gumbo T, Boorgula GD, Thomas TA, **Phillely JV**, Srivastava S. Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium *tuberculosis* in the hollow fiber system model. *Antimicrob Agents Chemother.* 2024 Feb 7;68(2).



## Other Academic Presentations (*Selected*)

---

**Philley, Julie,** Invited Grand Rounds. NTM-LD: Improving Diagnosis, Individualized Treatment, and Adherence. San Juan City Hospital, Puerto Rico, 2023

**Philley, Julie,** Invited Grand Rounds. NTM-LD: Improving Diagnosis, Individualized Treatment, and Adherence. LSU, Shreveport, LA, 2023

**Philley, Julie,** To Treat or Not to Treat: Contemporary Considerations in Treating MAC Lung Disease, 6<sup>th</sup> World Bronchiectasis Conference, New York, 2023

**Philley, Julie,** Airway Clearance in Bronchiectasis: An Interactive Session, 6<sup>th</sup> World Bronchiectasis Conference, New York, 2023

**Philley, Julie,** NTM Lung Disease: A Case Based Approach, France Foundation, 2023

**Philley, Julie,** Invited Grand Rounds NTM lung Disease: A Case Based Approach, UTSW ID, 2022

**Philley, Julie,:** A Case Based Approach NTM lung Disease, University of Connecticut, 2022

**Philley, Julie,** “Casirivimab with Imdevimab, a Cocktail of Two Antibodies Against SARS-CoV-2, in the Outpatient Setting: Phase 3 Efficacy and Safety Results” ATS International Conference, San Diego, CA, 2021.

**Philley, Julie,** Mycobacterium Avium Complex: Diagnosis and Treatment” Norton Institute, Lung Transplant Symposium, Scottsdale, AZ, 2020

**Philley, Julie,** Research Speaker, “UTHSCT NTM Research Update” Oregon Health & Science University, Portland, OR, 2019-2022.

**Philley, Julie,** Invited speaker for Post Graduate Course Nontuberculous Mycobacteria (NTM) at American Thoracic Society Conference, 2018-2022

**Philley, Julie,** Invited speaker for the NTM symposium, NYU, New York University, New York, NY, 2018-2021

**Philley, Julie,** Chest Immersion. CHEST. Nontuberculous Mycobacterial Disease. Los Angeles, CA, 2019.

**Philley, Julie,** “NTM & Bronchiectasis National Physician/Patient Conference,” The University of Texas Health Science Center at Tyler, Gaylord Texas Resort & Convention Center, Grapevine, TX, 2019

**Philley, Julie,** “Nontuberculous Mycobacteria: Best Practices in Diagnosing and Managing NTM,” NTM Symposium, San Antonio Marriott River Center, San Antonio, TX, 2018

## Letters to the Editor

Babb, T., Levine, B and **Philley, J.** ICU-Acquired Weakness: An Extension of the Effects of Bed Rest. Am J Respir Crit Care Med. 2012 Jan 15; 185 (2): 230-2.

## Videos

**Phillely, Julie Dr.** and Leitman, Philip “Kathryn Raaker’s World – NTM,”  
[https://www.youtube.com/watch?v=3E3Yzl5\\_S1Y](https://www.youtube.com/watch?v=3E3Yzl5_S1Y), January 13, 2019.

**Phillely, Julie Dr.**, “Mycobacterial Lung Infection: A Big Name for A Serious Problem,” <https://www.youtube.com/watch?v=cK26WVb4nKw>,  
University of Texas Health Science Center at Tyler – June 1, 2016.

**Phillely, Julie Dr.**, “When Pneumonia Walks,”  
<https://www.youtube.com/watch?v=pDCGdFXQW3A>, University of Texas  
Health Science Center at Tyler, October 19, 2013.

**Phillely, Julie Dr.**, “Pulmonary Hypertension,”  
<https://www.youtube.com/watch?v=YMgyyyDuapM>, University of Texas  
Health Science Center at Tyler, October 7, 2012.